Adi-Peg 20 Plus Docetaxel (Doc) In Men With Castrate Resistant Prostate Cancer (Crpc): Results From A Phase Ib Trial.

Ben Kent Tomlinson,John S. Bomalaski,Monica Diaz,Taiwo Akande,Tianhong Li,Thomas John Semrad,Karen Kelly,David R. Gandara,Chong-xian Pan,Primo Lara

JOURNAL OF CLINICAL ONCOLOGY（2015）

引用 0|浏览27

暂无评分

摘要

e16116 Background: ADI-PEG20 is a pegylated enzyme that degrades arginine, a required amino acid in argininosuccinate synthetase (ASS) deficient tumors. Immunohistochemical staining suggests most p...

查看译文

关键词

resistant prostate cancer,prostate cancer,docetaxel,adi-peg

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要